Dear Investors, Colleagues, and Friends,

By now, you have likely heard from us about SJP-001, our groundbreaking hangover prevention product. With over 2 billion people worldwide consuming alcohol and the global hangover cure market projected to reach $4.69 billion by 2028, SJP-001 is poised to make a significant impact as what hopes to be the first and only FDA-approved product in this space.

For thousands of years, alcohol consumption has been an integral part of human civilization, with evidence of fermented beverages dating back to ancient Egypt, China, and Greece. Despite its long history, the negative effects of alcohol, particularly hangovers, have persisted throughout the ages. While societies have sought various remedies to alleviate the unpleasant symptoms of hangovers, most of these solutions have been based on myths and anecdotal evidence rather than scientific research. We aim to change this narrative by setting a new standard in the hangover prevention market.

To learn more about SJP-001 and the opportunity to invest with us, please review our detailed Prospectus. Notably, for SJP-001, we offer an added incentive: a share of our annual revenues from licensing royalties. In our sprint to raise $3M for this asset's Phase 2 Clinical Trial, we have nearly completed the first $1M tranche, with only $300,000 left to achieve a potential 33X return on investment. The time to act is now: wefunder.com/senjam.

To hear me explain more about this Revenue Sharing component, please view this short three-and-a-half-minute clip:

If you have any questions or would like to discuss further, please contact us.

Best regards,

Jim